Cindy Collins

"Cindy is President and Chief Executive Officer of Editas Medicine. She joined Editas Medicine’s Board of Directors in December 2018, has served as interim CEO since March 2019, and was appointed permanent President and CEO in August 2019.

"Cindy is a recognized leader in gene and cell medicines, molecular diagnostics, life sciences, and therapeutics. Most recently, Cindy served as CEO of Human Longevity Inc. Prior, she served as CEO/GM of General Electric’s Healthcare Cell Therapy Business, Lab Businesses and Clarient Diagnostics, Inc. Cindy also served as President and CEO of GenVec, a publicly-traded vaccine and gene therapy company and before that, she served as Group Vice President, Cellular Analysis Business of Beckman Coulter with responsibility for its Hematology, Flow Cytometry, and Hemostasis businesses. Prior to Beckman Coulter, she served as President and CEO of Sequoia Pharmaceuticals, Inc., a venture-capital funded company developing antiviral drugs for HIV and HCV.

"Earlier in her career, Cindy served as President of Clinical Micro Sensors, Inc., a wholly-owned subsidiary of Motorola, a molecular diagnostic company. Prior to Motorola, she spent 17 years with Baxter Healthcare in a variety of executive roles, including President of Oncology, Vice President of Strategy and Portfolio Management of BioScience, Vice President and General Manager of Cell Therapies, and Vice President of Business Development of Transfusion Therapies. She began her career with Abbott Laboratories where she spent six years in various operating roles.

"Cindy received her BS degree in Microbiology from the University of Illinois, Urbana and her MBA, from The University of Chicago Booth School of Business. She is a member of the board of directors for the ARM Foundation for Cell and Gene Medicine, Triumvira Immunologics, DermTech, and Biocare Medical."